Danish biotech company Bactolife has raised more than €30m ($35.12m) in a series B financing round.
The round was led by Cross Border Impact Ventures and the Danish Export and Investment Fund, with participation from existing investors Novo Holdings and Athos.
The company is also backed by cornerstone investors including the Gates Foundation.
Bactolife develops Binding Proteins derived from camelid immunoglobulins and produced at scale via precision fermentation.
Its ingredients are designed for use in food, feed and dietary supplements.
The proceeds will support commercialisation of its Binding Proteins and fund a planned human study programme.
The studies are expected to take place across the US, Europe, Asia and low- and middle-income countries (LMICs).
Bactolife plans to launch its first Binding Protein products for human health in the US in 2026 under its Helm ingredient brand, with expansion into Asia and Europe to follow.
The company also aims to expand its production and distribution capacity worldwide, with a focus on bringing both human and animal health ingredients to market for use in dietary supplements, functional foods and beverages, and feed additives.
Bactolife CEO Sebastian Søderberg said: “Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026. This funding will enable us to clinically validate, scale, and commercialize our Binding Proteins, taking Bactolife’s solutions to a broad audience.
“We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission. We are ready to transform gut health with novel Binding Proteins.”
